COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina
Henderson et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkae042
https://c19early.org/henderson2.html